Tecentriq (Atezolizumab) vs Rybrevant (amivantamab-vmjw)

Tecentriq (Atezolizumab) is an immune checkpoint inhibitor that works by blocking the PD-L1 protein, which can help the immune system detect and fight cancer cells, and is used in various types of cancer, including non-small cell lung cancer (NSCLC), urothelial carcinoma, and others. Rybrevant (amivantamab-vmjw) is a bispecific antibody that targets EGFR and MET receptors and is specifically approved for the treatment of adult patients with NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, who have progressed on or after platinum-based chemotherapy. When deciding between these two medicines, it is crucial to consider the specific type of cancer, its genetic mutations, previous treatments, and overall health, as these factors will influence the effectiveness and suitability of the treatment.

Difference between Tecentriq and Rybrevant

Metric	Tecentriq (Atezolizumab)	Rybrevant (amivantamab-vmjw)
Generic name	Atezolizumab	Amivantamab-vmjw
Indications	Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer	Non-small cell lung cancer
Mechanism of action	PD-L1 inhibitor, immune checkpoint inhibitor	Bispecific antibody targeting EGFR and MET receptors
Brand names	Tecentriq	Rybrevant
Administrative route	Intravenous infusion	Intravenous infusion
Side effects	Fatigue, nausea, infections, decreased appetite, dyspnea, cough, arthralgia	Infusion-related reactions, rash, paronychia, musculoskeletal pain, dyspnea, nausea
Contraindications	None known	None known
Drug class	Monoclonal antibody, PD-L1 blocking antibody	Monoclonal antibody, bispecific EGFR and MET inhibitor
Manufacturer	Genentech (Roche)	Janssen Biotech, Inc.

Efficacy

Tecentriq (Atezolizumab) Efficacy in Lung Cancer

Tecentriq (Atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used in the treatment of lung cancer. It is particularly indicated for non-small cell lung cancer (NSCLC) and has shown efficacy in both first-line and second-line treatments. In clinical trials, Tecentriq has been shown to improve overall survival in patients with high PD-L1 expression when compared to chemotherapy alone. Specifically, in a study known as IMpower110, patients with metastatic NSCLC with high PD-L1 expression treated with Tecentriq had a median overall survival of 20.2 months compared to 13.1 months in those receiving chemotherapy.

For patients with small cell lung cancer (SCLC), Tecentriq has also demonstrated benefits. When combined with chemotherapy (carboplatin and etoposide), Tecentriq has improved overall survival in the first-line treatment of extensive-stage SCLC, as seen in the IMpower133 trial. The addition of Tecentriq to chemotherapy resulted in a median overall survival of 12.3 months versus 10.3 months for chemotherapy alone.

Rybrevant (Amivantamab-vmjw) Efficacy in Lung Cancer

Rybrevant (amivantamab-vmjw) is a bispecific antibody that targets epidermal growth factor receptor (EGFR) and MET receptor pathways. It is approved for the treatment of adult patients with NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Rybrevant's efficacy was evaluated in the CHRYSALIS study, a multicenter, non-randomized, open-label, multicohort study. Patients treated with Rybrevant showed a response rate of 40%, with a median duration of response of 11.1 months, indicating a significant clinical benefit for this patient population.

It is important to note that the efficacy of both Tecentriq and Rybrevant can vary based on individual patient factors, including biomarker status, disease stage, and prior treatments. These therapies represent significant advancements in the personalized treatment of lung cancer, but their use should be guided by a healthcare professional, taking into consideration the specific characteristics of each patient's cancer.

Regulatory Agency Approvals

Tecentriq

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Rybrevant

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tecentriq or Rybrevant today

If Tecentriq or Rybrevant are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tecentriq

Buy Rybrevant

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: